Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Suspended 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Dermatologic 1

Conditions

Pain 1Neoplasms 1Melanoma 1Hypotension 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × imisopasem manganese × Clear all
NCT00101621 2006-02-09

Pilot Study to Evaluate the Safety and Analgesic Activity of M40403 Co-Administered With an Opioid Agent for Cancer Pain

MetaPhore Pharmaceuticals

Phase 2 Terminated
24 enrolled

Neoplasms, Pain

NCT00033956 2005-06-24

Evaluation of M40403 for the Prevention of Dose Limiting Toxicities of High Dose IL-2

MetaPhore Pharmaceuticals

Phase 1/2 Suspended
48 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Hypotension, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡